The Effect of Secretome Hypoxia Mesenchymal Stem Cells (SH-MSCs) Cream on IL-6 Gene Expression (In Vivo Study on Psoriasis-like Rats Model Induced by SH-MSCs)

Abstract

Psoriasis is caused by chronic inflammation of the skin that occurs in various countries. Current therapy is still dominated by long-term anti-inflammatory which causes various side effects. Hypoxic secretome mesenchymal stem cells (SHMSCs) contain soluble molecule bioactive anti-inflammatory cytokines that can suppress inflammation. However, the role of SHMSCs on IL-6 gene expression in psoriasis-like has not been studied until now. The aim of this study was to determine the effect of SH-MSC administration on IL-6 gene expression in Psoriasis-like rats induced by IMQ 100 mg. The research design is an experimental posttest control group design. The experimental subject was divided into four treatment groups consisting of a healthy group (no treatment), positive control group (only IMQ 100 mg), P1 group (SH-MSC therapy 100 μL/kgBW in 100 mg cream) and P2 group (SH-MSCs therapy 200 µL/kgBW in 100 mg cream). P1 and P2 were given SH-MSC topically for 14 days. At the end of the treatment, termination, extraction skin and IL-6 gene expression analysis by qRT-PCR. The results of this study showed that the mean expression of the IL-6 gene in the healthy group was: 1.00±0.00; positive control: 6.16±1.19, P1: 3.06±1.65, P2: 1.06±0.41. Analysis data using Kruskal Wallis test with p<0.05 and Mann Whitney p<0.05 so that there was a significant difference between treatment group. The administration of SH-MSC had a significant effect on improving conditions in psoriasislike model rats as indicated by a decrease in IL-6 gene expression.